Mary Herrera
Family · Valencia, CANPI 1962700104
Payments from drug & device makers
Across 159 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$622
- AbbVie$597
- Lilly USA, LLC$404
- Novo Nordisk$282
- Pfizer$221
- Merck$176
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,385100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $622 |
| AbbVie | 28 | $597 |
| Lilly USA, LLC | 15 | $404 |
| Novo Nordisk | 14 | $282 |
| Pfizer | 12 | $221 |
| Merck | 8 | $176 |
| GSK | 8 | $145 |
| Amgen | 7 | $115 |
| Boehringer Ingelheim | 5 | $100 |
| Exact Sciences | 4 | $99 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $84 |
| Esperion Therapeutics, Inc. | 3 | $76 |
| Phathom Pharmaceuticals, Inc. | 4 | $74 |
| Eisai Inc. | 3 | $58 |
| Vertex | 2 | $55 |
| Corcept Therapeutics | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 1 | $29 |
| Novartis | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Genentech USA, Inc. | 2 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
How this compares
$3,385 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 30 | $21,104 |
| FarxigaDapagliflozin Propanediol | 11 | $9,925 |
| JanuviaSitagliptin Phosphate | 16 | $9,694 |
| Icosapent Ethyl | 13 | $2,600 |
| Gabapentin | 67 | $2,341 |
| Atorvastatin Calcium | 223 | $1,943 |
| SynthroidLevothyroxine Sodium | 43 | $1,898 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,565 |
| Losartan Potassium | 168 | $1,483 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,440 |
| Levothyroxine Sodium | 103 | $1,301 |
| ProgesteroneProgesterone, Micronized | 14 | $1,015 |
| Valsartan | 25 | $811 |
| Omeprazole | 51 | $750 |
| Rosuvastatin Calcium | 47 | $716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $100 | $21,10430 claims |
| AstraZenecaFarxiga | $622 | $9,92511 claims |
| MerckJanuvia | $176 | $9,69416 claims |
| AbbVieSynthroid | $597 | $1,89843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.
Other family in Valencia
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.